

Supplementary Table 6. Summary of drug repositioning for AIH and supporting evidence

Drug	P-value	Hepatotoxicity	Experimental evidence for AIH	Experimental evidence for other liver diseases	Clinical evidence for AIH	Clinical evidence for other liver diseases
Tocilizumab	8.13E-07	Exist				
Etonogestrel	0.000475	None				
Everolimus	0.000515	Exist				
Pioglitazone	0.000895	None		29634314		14752837
Tocilizumab	0.001004	Exist				
Medroxyprogesterone	0.00171	None		6446443		6446443
Dasatinib	0.002181	Exist				
Dexamethasone	0.002301	None	23523671	30900368	30900368	20973887
Paricalcitol	0.002356	None		33872698		
Lenalidomide	0.002494	Exist				
Losartan	0.003029	None		34360607		
Hydrocortisone	0.004513	None				
Estradiol	0.006212	None		33870713		
Calcitriol	0.007805	None	24171052	28596677	33151930	32966467
Rimonabant	0.012666	None		28363784		19112166

The numbers shown in the table represent PubMed Identifier (PMID) numbers, which provide evidence for the foundational research and clinical studies supporting the therapeutic effects of the respective drugs.
 AIH, Autoimmune hepatitis.